Biotech Roundup: Kadmon Debt, Hemo Data, Loose Lips & More
Xconomy
JUNE 17, 2016
. —Funding rounds: Cambridge-based Mersana Therapeutics closed a $33 million Series C round with the aim of testing its first drug, an antibody-drug conjugate for breast cancer called XMT-1522… Rockefeller University spinout Rgenix’s $33 million financing was the second largest for a privately held Manhattan biotech this year.
Let's personalize your content